Connective and Soft Tissue Neoplasm

In 41 patients with postbaseline scans, three patients with liposarcoma achieved a partial response (at 250, 400, and 500 mg), 31 showed stable disease, and eight had progressive disease. In total, 27… (full text at CIViC)

PMID 28240971 · Wagner et al., 2017 · Open in CIViC

Since significant ALK and MET expression was only detected in ARMS samples, the effect of crizotinib, an ATP competitive, MET and ALK inhibitor, was evaluated on the growth of RH4 and RH30 ARMS cell l… (full text at CIViC)

PMID 26445453 · Megiorni et al., 2015 · Open in CIViC

28 patients were selected from a cohort of 43 patients with clear-cell sarcoma (CCSA) for this phase II trial. 26 of such patients presented with EWSR1 rearrangement and MET overexpression (MET+ cohor… (full text at CIViC)

PMID 28950372 · Schöffski et al., 2017 · Open in CIViC

This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1… (full text at CIViC)

PMID 27562493 · Rekhi et al., 2016 · Open in CIViC

This study evaluated 641 cases of rhabdomyosarcoma (RMS), enrolled on Children’s Oncology Group trials (1998-2017) and UK malignant mesenchymal tumor and RMS2005 trials (1995-2016), for mutations in 3… (full text at CIViC)

PMID 34166060 · Shern et al., 2021 · Open in CIViC

This study evaluated 641 cases of rhabdomyosarcoma (RMS), enrolled on Children’s Oncology Group trials (1998-2017) and UK malignant mesenchymal tumor and RMS2005 trials (1995-2016), for mutations in 3… (full text at CIViC)

PMID 34166060 · Shern et al., 2021 · Open in CIViC

Sporadic and Neurofibromatosis Type 1 (NF1) related refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) showed no significant clinical benefit when treated with Everolimus in Combination with … (full text at CIViC)

PMID 31427883 · Widemann et al., 2019 · Open in CIViC

BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts

PMID 24373973 · Patel et al., 2014 · Open in CIViC

A 58-year-old male with NTRK-fusion positive gastrointestinal stromal tumour (GIST) demonstrated initial response to Larotrectinib but progressed after developing a gatekeeper mutation (TRKC F617L).

PMID 30624546 · Hong et al., 2019 · Open in CIViC

This is the first study showing the ETV6-NTRK3 gene fusion in congenital fibrosarcoma (CFS). Using cytogenetic and FISH analyses, a novel t(12;15)(p13;q25) rearrangement was identified in CFS cases (3… (full text at CIViC)

PMID 9462753 · Knezevich et al., 1998 · Open in CIViC

The majority of MPNST samples were positive for PARP staining. Overall, moderate to high expression of PARP1 and PARP2 was observed (Table 1)....Overall, treatment continued for 60 d at which point 5 … (full text at CIViC)

PMID 26650448 · Kivlin et al., 2016 · Open in CIViC

Study of combination of trabectedin + olaparib in sarcoma cell lines and xenograft models. Initial results found combination therapy significantly reduced colony growth (p<0.001) in high-PARP1-expres… (full text at CIViC)

PMID 28454547 · Pignochino et al., 2017 · Open in CIViC

In a cohort of 171 pediatric rhabdomyosarcoma patients, the PAX3::FOXO1 fusion transcript was detected in 55% of patients with centrally reviewed ARMS. Critically, this fusion, along with the related … (full text at CIViC)

PMID 12039929 · Sorensen et al., 2002 · Open in CIViC

In this study, a total of 147 rhabdomyosarcomas/normal pairs were analyzed, 44 by whole genome sequencing and 103 tumors by whole exome sequencing. 50 cases classified as alveolar rhabdomyosarcoma his… (full text at CIViC)

PMID 24436047 · Shern et al., 2014 · Open in CIViC

In a cohort of 171 uniformly treated pediatric rhabdomyosarcoma (RMS) patients, 78 patients had alveolar rhabdomyosarcoma (ARMS). Of ARMS patients, 55% harbored a PAX3-FOXO1 fusion, 22% harbored a PAX… (full text at CIViC)

PMID 12039929 · Sorensen et al., 2002 · Open in CIViC

In this study, a total of 147 rhabdomyosarcomas/normal pairs were analyzed, 44 by whole genome sequencing and 103 tumors by whole exome sequencing. 50 cases classified as alveolar rhabdomyosarcoma his… (full text at CIViC)

PMID 24436047 · Shern et al., 2014 · Open in CIViC

One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study an… (full text at CIViC)

PMID 29606586 · Laetsch et al., 2018 · Open in CIViC

In a pediatric phase 1 trial (NCT02637687), a boy aged 15 months with soft tissue sarcoma of the right upper thigh harbored the PDE4DIP-NTRK1 fusion. After resection and the failure of initial chemoth… (full text at CIViC)

PMID 30204247 · DuBois et al., 2018 · Open in CIViC

An 18-month-old female patient presented with a history of an enlarging, subcutaneous mass in her right lower extremity since birth. A biopsy was performed and the findings were typical of Dermatofibr… (full text at CIViC)

PMID 15503291 · Price et al., 2005 · Open in CIViC

In this retrospective study, two patients with locally advanced Dermatofibrosarcoma Protuberans (DFSP) and two patients with recurrent DFSP received imatinib treatment prior to undergoing Mohs surgery… (full text at CIViC)

PMID 19620561 · Han et al., 2009 · Open in CIViC

In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.

PMID 22745105 · Heinrich et al., 2012 · Open in CIViC

In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.

PMID 22745105 · Heinrich et al., 2012 · Open in CIViC

In an in vitro study, Ba/F3 cells expressing PDGFRA D842_M844delDIM mutation were associated withsensitivity to dasatinib treatment.(IC50: 10nM). Sensitivity was determined by assessing cell prolifera… (full text at CIViC)

PMID 18794084 · Dewaele et al., 2008 · Open in CIViC

GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.

PMID 15146165 · Lasota et al., 2004 · Open in CIViC

In a phase 2 trial, patients with gastrointestinal stromal tumor (GIST) harboring with PDGFRA D842V or other exon 18 mutation were treated with Avapritinib which have broad activity against oncogenic … (full text at CIViC)

Open in CIViC

In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.